Relay Therapeutics (RLAY) Equity Average (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Equity Average data on file, last reported at $604.6 million in Q1 2026.

• Equity Average for Q1 2026 came in at $604.6 million, down 19.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $604.6 million (down 19.32% YoY), and the FY2025 annual result was $672.4 million, down 12.09% from the prior year.
• Equity Average grew to $604.6 million in Q1 2026 per RLAY's latest filing, from $587.4 million in the prior quarter.
• Over five years, Equity Average peaked at $975.0 million in Q4 2022 and troughed at $587.4 million in Q4 2025.
• A 5-year average of $774.8 million and a median of $765.2 million in 2023 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2025: Equity Average soared 49.58% in 2022, then retreated 27.33% in 2025.
• A 5-year view of Equity Average shows it stood at $975.0 million in 2022, then fell by 21.52% to $765.2 million in 2023, then increased by 5.64% to $808.3 million in 2024, then dropped by 27.33% to $587.4 million in 2025, then advanced by 2.93% to $604.6 million in 2026.
• Business Quant data shows RLAY's Equity Average at $604.6 million in Q1 2026, $587.4 million in Q4 2025, and $636.7 million in Q3 2025.